Literature DB >> 27122978

Costs of cervical cancer treatment: population-based estimates from Ontario.

C Pendrith1, A Thind2, G S Zaric3, S Sarma4.   

Abstract

OBJECTIVES: The objectives of the present study were to estimate the overall and specific medical care costs associated with cervical cancer in the first 5 years after diagnosis in Ontario.
METHODS: Incident cases of invasive cervical cancer during 2007-2010 were identified from the Ontario Cancer Registry and linked to administrative databases held at the Institute for Clinical Evaluative Sciences. Mean costs in 2010 Canadian dollars were estimated using the arithmetic mean and estimators that adjust for censored data.
RESULTS: Mean age of the patients in the study cohort (779 cases) was 49.3 years. The mean overall medical care cost was $39,187 [standard error (se): $1,327] in the 1st year after diagnosis. Costs in year 1 ranged from $34,648 (se: $1,275) for those who survived at least 1 year to $69,142 (se: $4,818) for those who died from cervical cancer within 1 year. At 5 years after diagnosis, the mean overall unadjusted cost was $63,131 (se: $3,131), and the cost adjusted for censoring was $68,745 (se: $2,963). Inpatient hospitalizations and cancer-related care were the two largest components of cancer treatment costs.
CONCLUSIONS: We found that the estimated mean costs that did not account for censoring were consistently undervalued, highlighting the importance of estimates based on censoring-adjusted costs in cervical cancer. Our results are reliable for estimating the economic burden of cervical cancer and the cost-effectiveness of cervical cancer prevention strategies.

Entities:  

Keywords:  Cervical cancer; Ontario; censoring; cost estimates; population-based

Year:  2016        PMID: 27122978      PMCID: PMC4835018          DOI: 10.3747/co.23.2598

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  9 in total

Review 1.  Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies.

Authors:  Andrew H Briggs; Bernie J O'Brien; Gordon Blackhouse
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

2.  On the equivalence of some medical cost estimators with censored data.

Authors:  Hongwei Zhao; Heejung Bang; Hongkun Wang; Phillip E Pfeifer
Journal:  Stat Med       Date:  2007-10-30       Impact factor: 2.373

3.  Estimating medical costs from incomplete follow-up data.

Authors:  D Y Lin; E J Feuer; R Etzioni; Y Wax
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

4.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

5.  Cost analysis with censored data.

Authors:  Yijian Huang
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

6.  Five-year trends in mortality indices among gynecological cancer patients in Canada.

Authors:  Noori Akhtar-Danesh; Alice Lytwyn; Laurie Elit
Journal:  Gynecol Oncol       Date:  2012-09-01       Impact factor: 5.482

7.  Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan.

Authors:  Ralph P Insinga; Xin Ye; Puneet K Singhal; George W Carides
Journal:  Gynecol Oncol       Date:  2008-08-30       Impact factor: 5.482

8.  Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

Authors:  Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Kelvin Chan; Stuart Peacock; Murray D Krahn
Journal:  CMAJ Open       Date:  2013-01-16

9.  Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.

Authors:  Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Mahbubul Haq; Kelvin Chan; Winson Y Cheung; Jeffrey S Hoch; Stuart Peacock; Murray D Krahn
Journal:  CMAJ Open       Date:  2013-12-09
  9 in total
  7 in total

1.  HPV self-sampling: A promising approach to reduce cervical cancer screening disparities in Canada.

Authors:  M Vahabi; A Lofters
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

2.  Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-04-21

3.  The role of primary care Nurse Practitioners in reducing barriers to cervical cancer screening: A literature review.

Authors:  Elizabeth M King; David S Busolo
Journal:  Can Oncol Nurs J       Date:  2022-04-01

4. 

Authors:  Elizabeth M King; David S Busolo
Journal:  Can Oncol Nurs J       Date:  2022-04-01

5.  Women's sexual autonomy as a determinant of cervical cancer screening uptake in Addis Ababa, Ethiopia: a case-control study.

Authors:  Miresa Midaksa; Alemnew Destaw; Adamu Addissie; Eva Johanna Kantelhardt; Muluken Gizaw
Journal:  BMC Womens Health       Date:  2022-06-17       Impact factor: 2.742

6.  Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients.

Authors:  Irma M Puspitasari; Dewi Legianawati; Rano K Sinuraya; Auliya A Suwantika
Journal:  Int J Womens Health       Date:  2021-02-19

7.  Medical Cost to Treat Cervical Cancer Patients at a Social Security Third Level Oncology Hospital in Mexico City

Authors:  Víctor Granados-García; Patricia Piña-Sánchez; Nancy Reynoso-Noveron; Yvonne N Flores; Filiberto Toledano-Toledano; Gloria Estrada-Gómez; Teresa Apresa-García; Arely A Briseño
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.